Immune checkpoint inhibitors for ovarian cancer: A retrospective analysis of efficacy and tolerability.

e17574 Background: Ovarian cancer (OC) is the leading cause of gynecological cancer-related deaths. Despite standard treatments, most advanced cases recur within three years, highlighting the need for novel therapies. Although immune checkpoint inhibitors (ICIs) have shown limited benefits in OC so far, combining them with other treatments may improve outcomes. This study assesses the safety, tolerability, and antitumor efficacy of ICIs in OC patients in a real-world setting. Methods: Patients who had received at least one ICI treatment at Zhongnan Hospital of Wuhan University between January 1, 2018, and April 3, 2024, were enrolled. The primary endpoint was the confirmed objective response rate (ORR) according to RECIST version 1.1 criteria. Secondary endpoints included progression-free survival (PFS), overall survival (OS), and the incidence of adverse events (AEs). Results: A total of thirty-nine ovarian cancer patients (median age, 56 years) treated with ICIs were included in the analysis. Following a median follow-up period of 19.55 months, the ORR was determined to be 20.5%, comprising 2 complete responses and 6 partial responses. Additionally, 12 patients (30.8%) achieved stable disease. The median PFS was 6.3 months (95% CI, 3.8-8.8), while the median OS was 9.7 months (95% CI, 4.7-14.7). Earlier use of ICIs, platinum sensitiveness were associated with improved PFS. Treatment-related adverse events of grade 3 or higher were observed in 6 patients (15.38%). Conclusions: The study findings suggest that ICIs exhibit potential antitumor activity with manageable safety and toxicity profiles in patients with ovarian cancer, indicating the need for further investigation.